Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age ≥ 18 years
• Both males and females will be included
• Negative pregnancy test and effective contraception.
• Mild and moderate UC patients diagnosed and confirmed by an endoscope
Locations
Other Locations
Egypt
Tanta Unuversity
RECRUITING
Tanta
Contact Information
Primary
Mostafa Bahaa, PhD
mbahaa@horus.edu.eg
0201025538337
Time Frame
Start Date: 2023-02-28
Estimated Completion Date: 2026-06-20
Participants
Target number of participants: 60
Treatments
Active_comparator: Control Group
Mesalamine group will receive 1 g mesalamine three times daily for 6 months
Active_comparator: Fenofibrate group
Fenofibrate group will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months
Related Therapeutic Areas
Sponsors
Leads: Tanta University
Collaborators: Hend El-Said Abo Mansour, Faculty of Pharmacy, Menoufia University, Monir Hussein Bahgat, Faculty of Medicine, Mansura University